Tislelizumab |
Catalog No.GC65033 |
Tislelizumab, un anticuerpo monoclonal con alta afinidad de uniÓn al receptor PD-1, minimiza la uniÓn del receptor Fcγ en los macrÓfagos, anulando asÍ la fagocitosis dependiente de anticuerpos, un mecanismo de eliminaciÓn de células T y resistencia potencial a la terapia anti-PD-1.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1858168-59-8
Sample solution is provided at 25 µL, 10mM.
Tislelizumab, a monoclonal antibody with high binding affinity to the PD-1 receptor, minimizes Fcγ receptor binding on macrophages, thereby abrogating antibody-dependent phagocytosis, a mechanism of T cell clearance and potential resistance to anti-PD-1 therapy. Tislelizumab can be used for the research of advanced squamous non-small-cell lung cancer[1].
[1]. Jie Wang, et al. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 May 1;7(5):709-717.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *